RecruitingNCT02146170
Oncology
Thymic carcinoma
24
studies recruiting now
as of 7 Sept 2026
97
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
7 Jan 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT05104736
PT-112 in Subjects With Thymoma and Thymic Carcinoma
RecruitingPhase 1NCT06885697
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RecruitingPhase 2NCT07324629
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
RecruitingPhase 1NCT03295227
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 24 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Thymic carcinoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Thymic carcinoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
11 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Sacituzumab Govitecan (Trodelvy)
Phase 2Pemetrexed Disodium (Alimta)
Phase 2Sunitinib (Sunitinib accord)
Phase 2Sacituzumab Tirumotecan
Phase 2Ivonescimab
Phase 2Erfonrilimab
Phase 2Avelumab (Bavencio)
Phase 2Belinostat (Beleodaq)
+ 3 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).